We scan new podcasts and send you the top 5 insights daily.
Dr Sands says no one expects durvalumab to work differently from atezolizumab when paired with lurbinectedin. Even a positive durvalumab trial that merely matches atezolizumab data would still not answer the larger question of whether lurbinectedin belongs in first-line maintenance for extensive-stage SCLC at all.
The failure of the NRG LU005 trial, giving atezolizumab with chemoradiation, suggests concurrent radiation may harm local immune cells, undermining the checkpoint inhibitor's effect. This contrasts with the successful ADRIATIC trial, where durvalumab was given after chemoradiation, highlighting the critical importance of timing.
While lurbinectedin initially improves survival outcomes as maintenance therapy, long-term data shows the survival curves eventually converge. Experts interpret this to mean the drug provides a temporary, additive chemotherapy-like effect rather than a true synergy with immunotherapy that would produce a durable response and separate the "tails of the curves."
Dr Sands says that as IMforte data matured, the tails of the progression-free and overall survival curves came together. That convergence suggests the early hazard ratios may overstate how durable the lurbinectedin maintenance benefit is over time for extensive-stage SCLC in the first-line maintenance setting.
If the Delphi-305 trial for the T-cell engager Tarlatumab is positive in the first-line maintenance setting for small cell lung cancer, it would likely eliminate any clinical role for Lurbinectedin, another therapy currently used in that space. This highlights how a single trial outcome can dramatically reshape treatment standards and render existing options obsolete.
Data from the ADRIATIC trial surprisingly suggests the survival benefit of consolidation Durvalumab was more pronounced in patients receiving carboplatin versus cisplatin. This finding reassures clinicians about using the better-tolerated carboplatin in combination with chemoradiation for limited-stage small cell lung cancer, challenging the traditional preference for cisplatin.
Dr Sen says the biggest challenge to lurbinectedin maintenance is Delphi 305, which tests terlatumab plus durvalumab against durvalumab alone after induction chemoimmunotherapy. Its phase 3 results could reshape first-line maintenance before the durvalumab-lurbinectedin question matters, so it is the single key readout to watch.
Since the IMFORTE trial excluded patients with brain metastases, oncologists hold differing views. Some are purists and avoid it off-protocol, while others explain the lack of evidence (which isn't negative evidence) to the patient and consider it, especially if CNS disease is controlled, creating a personalized decision-making scenario.
In the MFORTE trial, the survival curves for the lurbinectedin-atezolizumab arm eventually converge with the atezolizumab-only arm. This indicates the combination provides an additive benefit (delaying progression) rather than true synergy, which would have created a more durable, long-term survival advantage.
The trial showed combining a CTLA-4 inhibitor (Tremelimumab) with a PD-L1 inhibitor (Durvalumab) significantly increased toxicity without improving efficacy over monotherapy. This result, consistent with other trials, questions the benefit-risk profile of dual checkpoint inhibition in the adjuvant setting for renal cell carcinoma.
Dr Sands says Lagoon’s second-line control arm had median overall survival above 10 months, which was surprising. Lurbinectedin’s initial FDA approval rested on a single-arm study with 9.3-month median survival, so today’s second-line comparator sets a higher bar than the old benchmark for relapsed disease.